Enhancing Solubility of Recombinant Proteins
By Dr. Zubair Khalid, DVM, MS, PhD ·
Quick Answer
- Choose solubility tags such as MBP or NusA when you need rapid screening of many constructs and can tolerate tag removal steps after purification.
- Choose chaperone co-expression such as GroEL/ES or DnaK when your target protein folds slowly or aggregates during translation and you can manage co-expression plasmid maintenance.
- Combine both strategies only after single-approach trials fail, because dual systems increase plasmid burden, metabolic load, and troubleshooting complexity.
At a Glance
| Strategy | Primary Mechanism | Typical Workflow Impact | Best Initial Use Case |
|---|---|---|---|
| MBP tag | N-terminal fusion that acts as a folding enhancer and improves solubility through hydrophobic surface shielding | Requires cloning a fusion construct, affinity purification, and protease cleavage to remove the tag | Small to medium proteins that express as inclusion bodies in E. coli |
| NusA tag | N-terminal fusion that slows translation and provides a large negatively charged surface to reduce aggregation | Requires cloning a fusion construct and often a second purification step after tag removal | Proteins with high hydrophobicity or those that are toxic to host cells |
| GroEL or GroES co-expression | Chaperonin system that captures unfolded proteins and provides an isolated folding chamber | Requires a second plasmid or an inducible operon, plus antibiotic selection for both plasmids | Proteins that misfold even when fused to a solubility tag |
| DnaK and DnaJ co-expression | Chaperone system that binds exposed hydrophobic patches and prevents aggregation during translation | Requires co-transformation and careful induction timing to avoid excess chaperone toxicity | Proteins that aggregate during translation instead of after full synthesis |
Understanding the Solubility Problem in Recombinant Protein Expression
Recombinant protein production in bacterial hosts frequently yields insoluble aggregates called inclusion bodies. These aggregates form when the protein concentration inside the cell exceeds the capacity of the host folding machinery, when the protein contains large hydrophobic patches, or when the protein requires post-translational modifications that bacteria cannot perform. The result is a protein that is biologically inactive and requires denaturation and refolding steps that often fail or produce low yields.
The decision between solubility tags and chaperone co-expression is not a choice between two equivalent tools. Each strategy addresses a different stage of the protein production pathway. Solubility tags act during translation and early folding by providing a well-folded fusion partner that drags the target protein into a soluble state. Chaperones act after translation by binding to exposed hydrophobic surfaces and guiding the protein through the folding process. Understanding this distinction is the first step in choosing the correct approach for a specific protein.
The molecular biology workflow begins with the cloning of the target gene into an expression vector. The choice of vector determines the promoter system, the fusion tag, and the selection marker. The Addgene protocols collection provides practical guidance for the cloning and transformation steps that precede any solubility test. These protocols are educational references and should be adapted to the specific expression system and host strain used in your laboratory.
The decision to use a solubility tag or a chaperone system also depends on the downstream application. A protein that will be used for structural studies may require the removal of the tag after purification. A protein that will be used for antibody production may tolerate the tag remaining in place. The cost of tag removal, including the protease and the additional purification step, must be factored into the decision.
Molecular Mechanisms of Solubility Tags
Solubility tags are fusion proteins that are attached to the N-terminus or C-terminus of the target protein. The tag provides a large, well-folded domain that promotes the solubility of the entire fusion protein. The most common tags are Maltose-Binding Protein (MBP) and NusA, each with a distinct mechanism of action.
MBP as a Folding Enhancer
MBP is a 42 kDa protein that binds maltose and maltodextrins. When fused to a target protein, MBP acts as a folding enhancer by providing a large, stable scaffold that can shield hydrophobic surfaces on the target protein. The mechanism is not fully understood, but the current model suggests that MBP binds to the target protein during translation and prevents the formation of aggregates by sequestering hydrophobic patches.
MBP is effective for a wide range of proteins, but it is not a universal solution. The tag must be removed after purification for many applications, which requires a specific protease cleavage site between the tag and the target protein. The cleavage step adds time and cost to the workflow and can introduce a risk of incomplete cleavage or precipitation of the target protein after the tag is removed.
The choice of MBP as a solubility tag is most appropriate when the target protein is small to medium in size and when the protein has a tendency to form inclusion bodies. The tag is less effective for very large proteins or for proteins that require specific post-translational modifications for folding.
NusA as a Translation Modulator
NusA is a 55 kDa protein that is involved in transcription termination and antitermination in bacteria. When fused to a target protein, NusA slows the rate of translation and provides a negatively charged surface that can reduce the aggregation of the target protein. The mechanism is thought to involve the interaction of NusA with the ribosome, which gives the target protein more time to fold during synthesis.
NusA is particularly effective for proteins that are prone to aggregation during translation. The tag is not as effective as MBP for proteins that misfold after translation is complete. NusA is also a relatively large tag, which can complicate the purification and downstream processing of the target protein.
The choice between MBP and NusA is often based on the specific protein and the experience of the laboratory. Some proteins respond better to one tag than the other, and the only way to know is to test both in parallel. The Addgene protocols collection includes guidance on the construction of fusion proteins and the selection of appropriate expression vectors.
Tag Removal and Its Impact on Solubility
The removal of a solubility tag is a critical step that can undo the benefits of the tag. When the tag is cleaved, the target protein is exposed to the solution without the protective scaffold. If the target protein has a strong tendency to aggregate, it may precipitate immediately after cleavage.
The choice of protease is important. The most common proteases are TEV protease and Factor Xa, which recognize specific amino acid sequences. The protease must be active under the conditions used for the target protein, and the cleavage reaction must be monitored to ensure complete removal of the tag.
The cost of the protease and the additional purification step must be included in the overall cost of the solubility tag strategy. For proteins that are used in structural studies, the tag removal is often necessary, and the cost is justified. For proteins that are used in assays or as antigens, the tag may be left in place, and the cost is reduced.
Molecular Mechanisms of Chaperone Co-Expression
Chaperone co-expression involves the simultaneous expression of the target protein and a chaperone system that assists in folding. The most common chaperone systems are the GroEL/GroES system and the DnaK/DnaJ/GrpE system. These systems are native to E. coli and are involved in the folding of many cellular proteins.
GroEL and GroES
GroEL is a large chaperone complex that forms a barrel-like structure with a central cavity. GroES is a co-chaperone that binds to GroEL and caps the cavity. The target protein enters the cavity and is folded in an isolated environment that prevents aggregation. The folding process requires ATP, and the GroEL/GroES system is essential for the folding of many proteins in E. coli.
The co-expression of GroEL and GroES with a target protein can improve the solubility of proteins that misfold or aggregate during folding. The system is particularly effective for proteins that are larger than the cavity of the GroEL complex, but it is not effective for all proteins.
The co-expression of GroEL and GroES requires a second plasmid or an engineered operon that contains the chaperone genes. The plasmid must be maintained in the host cell, and the expression of the chaperones must be induced at the same time as the target protein. The co-expression can increase the metabolic load on the cell and reduce the overall yield of the target protein.
DnaK and DnaJ System
The DnaK system is a chaperone system that binds to exposed hydrophobic patches on the target protein and prevents aggregation. DnaK is a 70 kDa protein that binds to the target protein and then releases it in an ATP-dependent manner. DnaJ is a co-chaperone that delivers the target protein to DnaK, and GrpE is a nucleotide exchange factor that facilitates the release of the target protein.
The DnaK system is effective for proteins that aggregate during translation or during the early stages of folding. The system is also effective for proteins that are partially folded and need to be stabilized. The co-expression of DnaK, DnaJ, and GrpE is required for the system to function.
The DnaK system is a more complex system than the GroEL system, and the co-expression of three proteins can be more difficult to manage. The system is also less effective for proteins that are already fully synthesized and have aggregated.
Chaperone Co-Expression and Plasmid Maintenance
The co-expression of chaperones requires the maintenance of two plasmids in the host cell. The first plasmid contains the target protein gene, and the second plasmid contains the chaperone genes. The two plasmids must have different selection markers to ensure that both are maintained in the cell.
The maintenance of two plasmids increases the metabolic burden on the host cell and can reduce the growth rate and the yield of the target protein. The co-expression of chaperones is also be toxic to the host cell if the chaperones are overexpressed. The expression of the chaperones must be carefully controlled to avoid toxicity.
The NIH Guidelines for Recombinant or Synthetic Nucleic Acid Molecules provide the official oversight context for the construction and use of recombinant plasmids. The guidelines require that the work be conducted in accordance with the appropriate biosafety level and that the institutional biosafety committee be notified of the work.
Comparative Effectiveness of Tags and Chaperones
The effectiveness of solubility tags and chaperone co-expression is not universal. The choice between the two strategies depends on the specific protein, the host cell, and the downstream application. The following table summarizes the key differences between the two approaches.
| Factor | Solubility Tags | Chaperone Co-Expression |
|---|---|---|
| Mechanism | Fusion to a well-folded protein that promotes solubility | Binding to the target protein to prevent aggregation |
| Cloning complexity | Requires a fusion construct and a protease cleavage site | Requires a second plasmid or an engineered operon |
| Purification | Requires tag removal for many applications | Does not require tag removal |
| Metabolic burden | Moderate, due to the large tag | High, due to the co-expression of chaperones |
| Effectiveness | Best for small to medium proteins | Best for proteins that misfold or aggregate |
| Cost | Higher due to the protease and purification | Lower for the chaperone plasmid but higher for the co-expression |
The choice between the two approaches is often made based on the protein and the experience of the laboratory. A common approach is to test both strategies in parallel and to select the one that gives the highest yield of soluble protein.
Parallel Testing of Tags and Chaperones
The most efficient way to determine the best strategy for a specific protein is to test multiple approaches in parallel. This requires the construction of several expression constructs, each with a different tag or chaperone system. The constructs are then expressed in the same host cell and the solubility of the target protein is measured.
The parallel testing approach is time-consuming and requires a significant investment in cloning and expression. The approach is also be cost-effective in the long run because it avoids the need to repeat the expression and purification steps with a suboptimal strategy.
The MIQE guidelines provide a framework for the reporting of quantitative experiments, including the need for appropriate controls and the transparency of the experimental design. The guidelines are not specific to protein expression, but they are a useful reference for the design and reporting of any quantitative experiment.
The Role of the Host Cell
The host cell is a critical factor in the solubility of the target protein. The E. coli strains that are used for protein expression have been engineered to improve the folding of the target protein. The strains that are deficient in the proteases that degrade the target protein are also be used.
The choice of the host cell is often made based on the target protein and the expression system. The host cell is also be engineered to express the chaperones that are needed for the folding of the target protein. The co-expression of the chaperones is then be achieved by the use of a plasmid that contains the chaperone genes.
The Biosafety in Microbiological and Biomedical Laboratories provides the biosafety principles and the risk assessment for the use of recombinant organisms. The guidelines require that the laboratory be aware of the risks associated with the use of the host cell and the recombinant DNA.
Practical Workflow for Solubility Enhancement
The practical workflow for enhancing the solubility of a recombinant protein involves several steps, from the initial cloning to the final purification. The workflow is designed to be systematic and to provide the information that is needed to make the decision between the tags and the chaperones.
Step 1: Design the Expression Construct
The first step is to design the expression construct. The construct includes the target protein gene, the promoter, the tag, and the selection marker. The design is based on the protein and the downstream application.
The choice of the promoter is important. The promoter determines the level of the expression of the target protein. The T7 promoter is a strong promoter that is commonly used for the expression of the recombinant proteins. The promoter is induced by the addition of IPTG, which is a chemical that is not metabolized by the host cell.
The choice of the tag is also important. The tag is chosen based on the protein and the downstream application. The MBP tag is a good choice for the proteins that are poorly soluble. The NusA tag is a good choice for the proteins that are prone to aggregation during translation.
Step 2: Clone the Construct
The second step is to clone the construct into the expression vector. The cloning is performed using the standard molecular biology techniques. The Addgene protocols provide the protocols for the cloning and the transformation of the expression vector.
The cloning is a critical step that requires the use of the appropriate restriction enzymes and the ligation of the insert into the vector. The cloning is also be performed using the Gibson assembly or the other methods of the DNA assembly.
The cloning is verified by the sequencing of the insert. The sequencing is important to ensure that the insert is correct and that there are no mutations that could affect the expression of the target protein.
Step 3: Transform and Express
The third step is to transform the expression vector into the host cell. The transformation is performed using the chemical or the electroporation method. The transformed cells are then selected on the agar plates that contain the appropriate antibiotic.
The expression of the target protein is then induced by the addition of the IPTG. The induction is performed at the appropriate temperature and for the appropriate time. The temperature and the time are optimized for the specific protein.
The expression is then analyzed by the SDS-PAGE to determine the level of the expression and the solubility of the target protein. The analysis is important to determine whether the target protein is expressed in the soluble or the insoluble fraction.
Step 4: The Purification
The fourth step is to purify the target protein. The purification is performed using the affinity chromatography, which is based on the tag that is fused to the target protein. The tag is then removed by the use of the protease, and the target protein is purified further.
The purification is a critical step that requires the optimization of the conditions. The conditions include the pH, the salt concentration, and the temperature. The optimization is important to ensure that the target protein is purified in the soluble form.
The purification is then analyzed by the SDS-PAGE and the Western blot. The analysis is important to determine the purity of the target protein and the yield.
Records and Measurements for Solubility Assessment
The assessment of the solubility of the target protein is a critical step in the workflow. The assessment is based on the measurement of the protein in the soluble and the insoluble fractions. The measurement is performed using the SDS-PAGE and the densitometry.
SDS-PAGE and Densitometry
The SDS-PAGE is a method that is used to separate the proteins based on their size. The proteins are then stained with the Coomassie blue, and the intensity of the bands is measured by the densitometry. The densitometry is used to determine the amount of the protein in the soluble and the insoluble fractions.
The densitometry is a semi-quantitative method that is used to compare the amount of the protein in the different fractions. The method is not as accurate as the other methods, but it is a useful for the initial assessment of the solubility.
The NIST Laboratory Programs provide the measurement science and the standards that are used for the calibration of the instruments and the quality of the measurements. The standards are important for the accuracy and the reproducibility of the measurements.
Quantitative Solubility Assays
The quantitative solubility assays are used to measure the amount of the soluble protein in a more accurate manner. The assays include the Bradford assay and the BCA assay. The assays are based on the colorimetric detection of the protein.
The Bradford assay is a simple and a rapid method that is used to measure the protein concentration. The assay is based on the binding of the Coomassie Blue to the protein, which is then measured at the absorbance of 595 nm.
The BCA assay is a more sensitive method that is used to measure the protein concentration. The assay is based on the reduction of the copper ions by the protein, which is then detected by the bicinchoninic acid.
The choice of the assay is based on the protein and the buffer. The Bradford assay is not compatible with the detergents, and the BCA assay is not compatible with the reducing agents.
Reproducibility and Controls
The reproducibility of the solubility measurement is important for the comparison of the different strategies. The measurement is performed in the triplicate, and the average and the standard deviation are calculated.
The controls are also important. The control is a protein that is known to be soluble, and the control is used to ensure that the measurement is accurate. The control is also used to ensure that the expression and the purification are working correctly.
The MIQE guidelines provide the framework for the reporting of the quantitative experiments. The guidelines require the transparency of the experimental design and the use of the appropriate controls.
Common Failure Patterns and Troubleshooting
The failure of the solubility enhancement is a common problem. The failure is due to the several factors, including the protein, the host cell, and the expression conditions. The following are the common failure patterns and the solutions.
The Protein Is Still Insoluble
The protein is still insoluble after the use of the tag or the chaperone. The failure is due to the protein that is not compatible with the tag or the chaperone. The solution is to try a different tag or a different chaperone.
The protein is also be insoluble because the protein is too large or because the protein requires the post-translational modifications. The solution is to use a different host cell that is able to provide the modifications.
The Protein Is Expressed but Not Soluble
The protein is expressed but is not soluble. The failure is due to the expression conditions. The solution is to reduce the temperature of the expression and to reduce the concentration of the IPTG.
The protein is also be expressed but is not soluble because the protein is aggregated during the expression. The solution is to use a chaperone that is able to prevent the aggregation.
The Protein Is Soluble but Is Not Active
The protein is soluble but is not active. The failure is due to the protein that is not folded correctly. The solution is to use a chaperone that is able to fold the protein correctly.
The protein is also be soluble but is not active because the protein is not modified. The solution is to use a host cell that is able to provide the modifications.
The Protein Is Degraded
The protein is degraded during the expression. The failure is due to the protease that is present in the host cell. The solution is to use a host cell that is deficient in the protease.
The protein is also be degraded because the protein is not stable. The solution is to use a tag that is able to stabilize the protein.
Safety and Regulatory Context
The expression of the recombinant proteins is subject to the biosafety and the regulatory oversight. The Biosafety in Microbiological and Biomedical Laboratories provides the guidelines for the safe handling of the recombinant organisms. The guidelines require that the laboratory be aware of the risks and the appropriate containment.
The NIH Guidelines for Recombinant or Synthetic Nucleic Acid Molecules provide the official oversight for the recombinant DNA work. The guidelines require that the work be conducted in a manner that is consistent with the appropriate biosafety level.
The laboratory is also required to have the institutional biosafety committee that reviews the work. The committee is responsible for the oversight of the work and the approval of the protocols.
The safety considerations are important for the protection of the laboratory workers and the environment. The safety is also important for the compliance with the regulations.
Professional Escalation Criteria
The professional escalation is the process of the escalation of the problem to the supervisor or the expert. The escalation is important when the problem is not solved by the standard troubleshooting.
The escalation is also important when the problem is a safety concern. The safety concern is the use of the recombinant organism that is not approved.
The escalation is also important when the problem is a regulatory concern. The regulatory concern is the use of the recombinant organism that is not in compliance with the regulations.
The escalation is also important when the problem is a quality concern. The quality concern is the protein that is not of the quality that is required for the downstream application.
The escalation is also important when the problem is a cost concern. The cost concern is the cost of the expression that is too high.
Decision Framework for Selecting Between Tags and Chaperones
The choice between solubility tags and chaperone co-expression is often treated as a binary decision, but the most effective approach depends on a structured evaluation of the target protein's properties, the expression system, and the downstream application. A decision framework that scores protein characteristics and experimental constraints can reduce the trial-and-error burden and provide a defensible rationale for the chosen strategy.
Step 1: Characterize the Target Protein
Before selecting any solubility enhancement strategy, collect the following information about the target protein. This characterization step takes one to two days and requires only basic bioinformatics tools and the protein sequence.
| Protein Property | Data Source | Relevance to Strategy Choice |
|---|---|---|
| Molecular weight | Sequence analysis | Tags are most effective below 60 kDa, larger proteins may require chaperones |
| Hydrophobicity score | Kyte-Doolittle or similar algorithm | High hydrophobicity predicts aggregation and favors chaperone systems |
| Predicted disordered regions | DisProt or IUPred | Disordered regions reduce tag effectiveness |
| Cysteine content | Sequence analysis | Disulfide bonds require oxidizing conditions that E. coli cannot provide |
| Transmembrane domains | TMHMM or similar | Membrane proteins require specialized systems beyond either strategy |
| Codon adaptation index | Sequence analysis | Low values suggest codon optimization may be needed before solubility work |
Record these values in a laboratory notebook or spreadsheet. The NIST Laboratory Programs provide measurement science guidance that supports consistent data recording and instrument calibration for the analytical steps that follow.
Step 2: Score the Candidate Strategies
Use the following scoring matrix to compare solubility tags and chaperone co-expression for your specific protein. Assign a score of 1 to 5 for each criterion, where 5 indicates the strategy is strongly preferred.
| Criterion | Solubility Tag Score | Chaperone Co-Expression Score |
|---|---|---|
| Protein size under 50 kDa | 5 | 3 |
| Protein size over 50 kDa | 2 | 4 |
| High hydrophobicity | 2 | 5 |
| Aggregation during translation | 3 | 5 |
| Aggregation after synthesis | 4 | 3 |
| Tag removal required for downstream use | 2 | 5 |
| Tag tolerated in final product | 5 | 5 |
| Single plasmid preferred | 5 | 2 |
| Two plasmid maintenance acceptable | 2 | 5 |
| Rapid screening of multiple constructs | 5 | 2 |
| Cost sensitivity | 3 | 4 |
Total the scores for each column. The strategy with the higher total is the preferred first approach. A score difference of less than 5 points indicates that parallel testing of both strategies is warranted. A score difference of 10 points or more indicates a clear first choice.
Step 3: Apply the Decision Rules
The scoring matrix provides a starting point, but the following decision rules refine the choice based on common experimental scenarios.
Rule 1: Small protein with high hydrophobicity. A protein under 30 kDa with a high hydrophobic score is a candidate for MBP tagging. The MBP tag shields hydrophobic surfaces during translation. If the protein still aggregates after MBP tagging, proceed to chaperone co-expression.
Rule 2: Large protein with slow folding kinetics. A protein over 60 kDa that aggregates during translation is a candidate for GroEL or GroES co-expression. The chaperonin system provides an isolated folding chamber that accommodates larger proteins. A solubility tag alone is unlikely to solve the aggregation problem.
Rule 3: Protein that aggregates after synthesis. A protein that remains soluble during translation but precipitates after full synthesis is a candidate for DnaK and DnaJ co-expression. This system binds exposed hydrophobic patches on the fully synthesized protein.
Rule 4: Downstream application requires tag-free protein. If the final application requires the removal of the tag, the cost of the protease and the additional purification step must be included in the decision. Chaperone co-expression avoids this cost because the chaperones are not fused to the target protein.
Rule 5: Multiple constructs to screen. If the laboratory is screening several protein variants or mutants, the solubility tag approach is more efficient because the same tag can be used for all constructs. Chaperone co-expression requires the maintenance of a second plasmid for each construct.
Step 4: Implement the Chosen Strategy
After the decision is made, implement the chosen strategy using the following sequence.
For a solubility tag approach:
- Clone the target gene into an expression vector with the chosen tag. The Addgene protocols provide the cloning and transformation steps.
- Transform the construct into the expression host.
- Express the protein at a reduced temperature, typically 16 to 25 degrees Celsius, to slow the translation and allow the tag to act.
- Lyse the cells and separate the soluble and insoluble fractions.
- Analyze the fractions by SDS-PAGE to determine the solubility.
For a chaperone co-expression approach:
- Clone the target gene into the expression vector with the appropriate selection marker.
- Transform the chaperone plasmid into the host cell and select for both plasmids.
- Induce the chaperone expression first, then induce the target protein expression after a delay of 30 to 60 minutes.
- Lyse the cells and separate the soluble and insoluble fractions.
- Analyze the fractions by SDS-PAGE.
The induction timing is a critical variable for chaperone co-expression. The chaperones must be present in sufficient quantity before the target protein is synthesized. The NIH Guidelines for Recombinant or Synthetic Nucleic Acid Molecules provide the oversight context for the construction and use of the recombinant plasmids in this workflow.
Step 5: Evaluate the Result and Decide on Next Steps
After the first expression trial, record the following measurements:
- Total protein concentration in the soluble fraction
- Total protein concentration in the insoluble fraction
- Percentage of the target protein in the soluble fraction
- The yield of the target protein per liter of culture
- The time required for the expression and the purification
If the soluble percentage is above 50 percent, the strategy is acceptable for most downstream applications. If the soluble percentage is below 20 percent, the strategy has failed and the alternative approach should be tested. If the soluble percentage is between 20 and 50 percent, the strategy may be improved by adjusting the expression conditions.
Step 6: Optimize the Expression Conditions
The expression conditions can be optimized to improve the solubility of the target protein. The following parameters are the most common variables to adjust.
Temperature. Lower temperatures slow the translation and the folding, which can reduce the aggregation. The temperature is typically reduced from 37 to 16 or 25 degrees Celsius. The optimal temperature is protein-specific and must be determined empirically.
Inducer concentration. The concentration of IPTG determines the rate of the protein synthesis. A lower concentration of IPTG reduces the rate of the synthesis and can improve the solubility. The concentration is typically reduced from 1 mM to 0.1 or 0.5 mM.
Induction time. The duration of the induction affects the accumulation of the protein. A shorter induction time can reduce the aggregation but also reduces the yield. The induction time is typically 2 to 6 hours for the chaperone co-expression and 4 to 16 hours for the tag approach.
Media composition. The addition of the glucose to the media can reduce the basal expression of the target protein. The addition of the sorbitol or the glycine betaine can stabilize the protein. The media composition is a less common variable but can be important for the specific protein.
The optimization is performed by the systematic variation of one parameter at a time. The results are recorded in a table that shows the soluble percentage for each condition. The MIQE guidelines provide the framework for the reporting of the quantitative experiments, including the need for the appropriate controls and the transparency of the experimental design.
Step 7: Document the Decision and the Results
The decision framework is only useful if the results are documented in a consistent format. The following record template is recommended for each protein tested.
| Field | Entry |
|---|---|
| Protein name and identifier | |
| Molecular weight | |
| Hydrophobicity score | |
| Strategy tested first | |
| Strategy score from the matrix | |
| Expression temperature | |
| Inducer concentration | |
| Soluble percentage | |
| Yield of the soluble protein | |
| Time to complete the expression | |
| Cost of the reagents | |
| Decision for the next step |
The documentation is used to compare the strategies across the different proteins in the laboratory. The documentation is also used to identify the patterns that predict the success of the strategy for the new proteins.
Step 8: Escalate When the Framework Does Not Resolve the Problem
The decision framework is not a guarantee of the success. Some proteins are not soluble with any of the strategies described in this article. The following criteria indicate that the problem should be escalated to a supervisor or a specialist.
Escalation criterion 1: The protein is insoluble with both the tag and the chaperone. If the protein remains insoluble after the testing of the MBP tag, the NusA tag, the GroEL or GroES system, and the DnaK system, the problem is likely to be the protein itself. The protein may require a different host cell, a different expression system, or a refolding protocol.
Escalation criterion 2: The protein is soluble but is not active. If the protein is soluble but the activity is not detected, the protein is likely to be misfolded. The misfolding is not be corrected by the solubility tag or the chaperone. The protein may require the post-translational modifications that the bacterial host cannot provide.
Escalation criterion 3: The protein is degraded during the expression. If the protein is degraded, the host cell is likely to be the problem. The host cell may be deficient in the protease or the protein may be unstable. The protein may require a different host strain or a different expression system.
Escalation criterion 4: The cost of the strategy exceeds the budget. If the cost of the tag removal or the chaperone co-expression exceeds the budget for the project, the strategy is not viable. The protein may be produced by a different method, such as the cell-free expression or the mammalian cell expression.
The escalation is documented in the laboratory notebook and the supervisor is notified. The Biosafety in Microbiological and Biomedical Laboratories provides the biosafety principles and the risk assessment for the use of the recombinant organisms in the laboratory. The escalation is also documented for the regulatory compliance.
Common Failure Patterns in the Decision Framework
The decision framework fails when the laboratory does not follow the steps in the correct order or when the laboratory does not record the results. The following are the common failure patterns.
Failure pattern 1: The laboratory skips the protein characterization. The laboratory selects the tag or the chaperone without the characterization of the protein. The result is the strategy that is not matched to the protein and the failure of the expression.
Failure pattern 2: The laboratory does not test the alternative strategy. The laboratory tests the primary strategy and the protein is insoluble. The laboratory does not test the alternative strategy and the protein is not expressed. The result is the protein that is not available for the downstream application.
Failure pattern 3: The laboratory does not optimize the expression conditions. The laboratory tests the strategy at the standard conditions and the protein is insoluble. The laboratory does not optimize the temperature or the inducer concentration. The result is the protein that is not soluble.
Failure pattern 4: The laboratory does not record the results. The laboratory tests the strategy but does not record the results. The laboratory cannot compare the strategies or identify the patterns. The result is the repeated testing of the same strategy.
The decision framework is a practical tool that is used to reduce the trial and error in the solubility enhancement. The framework is not a substitute for the experimental testing but is a way to prioritize the testing and to document the results. The framework is also a way to communicate the decision to the supervisor and to the other members of the laboratory.
The Role of the Measurement Standards
The measurement of the solubility is a critical step in the decision framework. The measurement is performed using the SDS-PAGE and the densitometry or the quantitative assays. The accuracy of the measurement is important for the comparison of the strategies.
The NIST Laboratory Programs provide the measurement science and the standards that are used for the calibration of the instruments and the quality of the measurements. The standards are important for the accuracy and the reproducibility of the measurements.
The calibration of the spectrophotometer is performed using the known standards. The calibration is performed before the measurement of the protein concentration. The calibration is also performed after the measurement to ensure that the instrument is stable.
The reproducibility of the measurement is assessed by the repeated measurement of the same sample. The measurement is performed in the triplicate and the average and the standard deviation are calculated. The standard deviation is used to determine the confidence in the measurement.
The MIQE guidelines provide the framework for the reporting of the quantitative experiments. The guidelines require the transparency of the experimental design and the use of the appropriate controls. The guidelines are not specific to the protein expression but are a useful reference for the design and the reporting of any quantitative experiment.
The Decision Framework in the Context of the Laboratory Workflow
The decision framework is integrated into the laboratory workflow. The framework is used at the beginning of the protein expression project. The framework is also used when the protein is not soluble with the initial strategy.
The framework is used to decide whether to use the tag or the chaperone. The framework is also used to decide whether to combine the two strategies. The combination of the tag and the chaperone is used when the protein is not soluble with the tag or the chaperone alone.
The combination of the tag and the chaperone is more complex and more expensive than the single strategy. The combination is used only after the single strategy has failed. The combination is also used when the protein is large and the tag is not sufficient to prevent the aggregation.
The combination of the tag and the chaperone is performed by the co-expression of the tagged protein and the chaperone. The tagged protein is expressed from the first plasmid and the chaperone is expressed from the second plasmid. The two plasmids are maintained in the host cell by the selection of the two antibiotics.
The combination of the tag and the chaperone is also performed by the fusion of the chaperone to the tag. The chaperone is fused to the tag and the target protein is fused to the chaperone. The fusion protein is expressed from the single plasmid and the chaperone is not expressed separately.
The combination of the tag and the chaperone is a more complex strategy that requires the careful optimization of the expression conditions. The combination is also more expensive than the single strategy. The combination is used only when the single strategy is not sufficient.
The decision framework is a practical tool that is used to reduce the problem of the insoluble protein. The framework is based on the characterization of the protein and the scoring of the candidate strategies. The framework is also based on the recording of the results and the optimization of the expression conditions. The framework is used to make the decision between the tag and the chaperone and to decide when to combine the two strategies.
Frequently Asked Questions
What is the difference between a solubility tag and a chaperone?
A solubility tag is a fusion protein that is attached to the target protein and promotes the solubility of the entire fusion. A chaperone is a protein that binds to the target protein and prevents the aggregation. The tag acts at the level of the translation and the early folding, while the chaperone acts at the level of the folding.
When should I use a solubility tag instead of a chaperone?
Use a solubility tag when the target protein is small to medium in size and when the protein is poorly soluble. Use a chaperone when the protein is large or when the protein is prone to aggregation during the folding.
Can I use both a solubility tag and a chaperone?
Yes, you can use both a solubility tag and a chaperone. The combination is used when the protein is not soluble with the tag or the chaperone alone. The combination is more expensive and more complex.
How do I know if my protein is soluble?
The solubility of the protein is determined by the SDS-PAGE. The protein is expressed and the cells are lysed. The soluble and the insoluble fractions are separated by the centrifugation. The protein is then analyzed by the SDS-PAGE.
What is the cost of the solubility tag and the chaperone?
The cost of the solubility tag is the cost of the cloning and the purification. The cost of the chaperone is the cost of the co-expression and the purification. The cost of the combination is the cost of the two.
What is the best solubility tag for my protein?
The best solubility tag is the tag that is the most effective for the protein. The tag is the MBP or the NusA. The tag is tested in the parallel.
What is the best chaperone for my protein?
The best chaperone is the chaperone that is the most effective for the protein. The chaperone is the GroEL or the DnaK. The chaperone is tested in the parallel.
What is the yield of the soluble protein?
The yield of the soluble protein is the amount of the protein that is in the soluble fraction. The yield is measured by the Bradford assay or the BCA assay. The yield is the amount of the protein that is the purified.
Related Molecular Biology Guides
- Recombinant Protein Solubility Expression: Key Factors and Strategies
- Contract Recombinant Protein Expression: A Comprehensive Guide
- Custom Recombinant Protein Expression: A Practical Guide
- Recombinant MICB Protein Expression: A Practical Guide
- Recombinant Technology for Protein Expression: A Comprehensive Guide
References and Further Reading
- Molecular Biology and Laboratory Methods. National Library of Medicine.
- Biosafety in Microbiological and Biomedical Laboratories. CDC and NIH.
- NIH Guidelines for Recombinant or Synthetic Nucleic Acid Molecules. National Institutes of Health.
- Addgene Protocols. Addgene.
- MIQE Guidelines. Clinical Chemistry.
- NIST Laboratory Programs. National Institute of Standards and Technology.
- Affinity Tags for Protein Purification.. Current protein & peptide science, 2020.
- Tagging Recombinant Proteins to Enhance Solubility and Aid Purification.. Methods in molecular biology (Clifton, N.J.), 2023.
- Role of arginine in protein refolding, solubilization, and purification.. Biotechnology progress, 2004.
- Tandem SUMO fusion vectors for improving soluble protein expression and purification.. Protein expression and purification, 2015.
- Synthetic intrinsically disordered protein fusion tags that enhance protein solubility.. Nature communications, 2024.
This article is educational and does not replace validated laboratory procedures, institutional biosafety review, manufacturer instructions, or professional interpretation.